ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026 - The Manila Times
ITM Announces Phase 3 COMPETE Patient-Reported Quality of Life Data with n.c.a. ¹⁷⁷Lu-edotreotide (ITM-11) vs. Everolimus at ASCO 2026 The Manila Times
Original source: Google News